| Literature DB >> 33854550 |
Abstract
BACKGROUND: Emerging of multidrug-resistant bacteria can compromise the effectiveness of antibiotics used to treat skin infections. Those bacteria imposed public health problems and questioning medical care in the 21st century. In this circumstance, essential oils of medicinal plants origin are supreme sources of structural and functionally divergent compounds, which inhibited the growth of common wound colonizing MRSA and ESBL producing P. aeruginosa. The aim of this study was to evaluate the combined antibacterial activity of essential oils extracted from Rumex abyssinicus, Cucumis pustulatus, and Discopodium penninervium against multidrug-resistant (MDR) isolates of skin ulcers.Entities:
Year: 2021 PMID: 33854550 PMCID: PMC8019382 DOI: 10.1155/2021/6680668
Source DB: PubMed Journal: Int J Microbiol
Antibiotics resistant profile of multidrug-resistant bacteria isolated from wounds at KMU, 2020.
| Modern drugs | Drug susceptibility test for multidrug bacteria strains isolated from wound samples | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ef1 | Ef2 | Ef3 | A1 | A2 | A3 | Ec1 | Ec2 | Ec3 | Ar1 | Ar2 | Ar3 | K1 | K2 | K3 | |
| Ciprofloxacin | R | R | I | R | I | R | R | R | R | R | S | I | R | I | R |
| Cefoxitin | R | I | R | R | R | R | N | N | N | N | N | N | N | N | N |
| Cefuroxime | S | R | I | N | N | N | R | R | R | R | R | R | I | R | I |
| Ceftriaxone | S | I | R | N | N | N | I | R | R | R | R | R | R | R | R |
| Ceftazidime | N | N | N | N | N | N | R | I | R | R | R | R | R | S | I |
| Chloramphenicol | R | R | R | S | R | I | R | R | S | R | R | R | S | R | R |
| Ampicillin | I | S | S | R | R | R | S | R | R | S | R | R | R | R | R |
| Augmentin | R | I | S | R | I | S | R | R | I | R | S | R | R | I | S |
| Amikacin | R | R | R | R | R | R | N | N | S | R | R | R | I | R | S |
| Erythromycin | R | I | R | R | R | I | R | I | R | R | R | R | S | S | R |
| Tetracycline | R | S | I | R | R | R | I | I | R | R | R | R | S | R | I |
| Penicillin | R | I | R | R | R | R | R | R | R | R | R | R | R | I | R |
| Vancomycin | R | R | R | I | R | S | N | N | N | N | N | N | N | N | N |
| Gentamycin | R | I | S | R | R | R | S | R | R | S | R | I | S | R | R |
A = methicillin resistant S. aureus; Ar = ESBL producing P. aeruginosa; Ec = ESBL producing E. coli; N = not done; Ef = Vancomycin resistant E. faecalis; K = multidrug-resistant K. pneumoniae; I = intermediate (17–20 mm IZ); R = resistance (≤16 mm IZ); S = sensitive (≥21 mm IZ) according to CLSI guidelines [25].
Inhibition zone (mm) of essential oils against MDR bacteria isolated from wounds at KMU, 2020.
| Essential oils, 50 |
| Inhibition zone in diameter (mm), pathogen bacteria isolated from wounds | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-positive bacteria | Gram-negative bacteria | ||||||||||
|
|
|
|
|
| |||||||
| ATCC | MRSA | ATCC | VRE | ATCC | ESBL | ATCC | MDR | ATCC | ESBL | ||
|
| 20 | 23 ± 0.8 | 23 ± 3.0 | 25 ± 1.3 | 25 ± 1.5## | 21 ± 0.7 | 22 ± 0.2₫ | 25 ± 0.5 | 25 ± 0.9$ | 21 ± 0.8 | 20.9 |
| 10 | 17 ± 0.4 | 18 ± .0.1 | 20 ± 0.9 | 19 ± 1.0 | 11 ± 0.3 | 12 ± 1.4 | 17 ± 1.7 | 17 ± 0.1 | 14 ± 1.2 | 14 ± 2.1 | |
| 5 | 10 ± 1.7 | 9 ± .0.9 | 14 ± 1.0 | 13 ± 1.5 | NI | NI | 11 ± 0.6 | 10 ± 1.1 | 8 ± 2.0 | 9 ± 0.1 | |
|
| |||||||||||
|
| 20 | 20 ± 2.0 | 21 ± 0.5 | 22 ± 0.1 | 22 ± 1.0# | 19 ± 0.8 | 18 ± 0.1 | 26 ± 0.7 | 26 ± 0.4$ | 21 ± 0.9 | 22 ± 0.3 ¥ |
| 10 | 13 ± 0.1 | 14 ± .0.3 | 17 ± 0.4 | 16 ± 0.7 | 14 ± 0.7 | 15 ± 1.0 | 18 ± 0.1 | 17 ± 0.5 | 17 ± 0.6 | 17 ± 0.7 | |
| 5 | 7 ± 0.7 | 8 ± .0.9 | 11 ± 0.1 | 9 ± 1.3 | 9 ± 1.6 | 8 ± 1.0 | 12 ± 1.9 | 9 ± 0.1 | NI | NI | |
|
| |||||||||||
|
| 20 | 19 ± 0.1 | 19 ± 0.2 | 20 ± 0.1 | 21 ± 0.1# | 12 ± 0.7 | 12 ± 1.1 | 22 ± 0.3 | 22 ± 0.4 | 19 ± 0.3 | 19 ± 0.4 |
| 10 | 10 ± 0.5 | 9 ± 0.2 | 12 ± 0.6 | 14 ± 0.6 | NI | NI | 13 ± 0.4 | 13 ± 0.9 | 8 ± 0.4 | 11 ± 0.9 | |
| 5 | NI | NI | 9 ± 0.6 | 8 ± 0.3 | NI | NI | 7 ± 0.6 | 10 ± 0.6 | NI | NI | |
|
| |||||||||||
| Positive control | S | R | S | R | S | R | S | R | S | R | |
| Negative control (5% DMSO) | NI | NI | NI | NI | NI | NI | NI | NI | NI | NI | |
Mean ± SD, C = ciprofloxacin; NI = no inhibition zone; NT = not tested; ATCC = susceptible >21 mm IZ, resistant <16 mm IZ, where P < 0.05 when compared to cefoxitin-treated MRSA, while #P < 0.05 and ##P < 0.01 when compared to modern drug treated E. faecalis and $P < 0.05 when compared to K. pneumoniae; ¥P < 0.05 when compared to modern drug treated P. aeruginosa, and ₫P < 0.05 when compared to modern drug treated E. coli.
Inhibition zone (mm) of combined essential oils against MDR bacteria isolated from wounds at KMU, 2020.
| Essential oils, 50 |
| Inhibition zone in diameter (mm), pathogen bacteria isolated from wounds | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-positive bacteria | Gram-negative bacteria | ||||||||||
|
|
|
|
|
| |||||||
| ATCC | MRSA | ATCC | VRE | ATCC | ESBL | ATCC | MDR | ATCC | ESBL | ||
|
| 20 | 29 ± 2.1 | 29 ± 1.3 | 31 ± 1.3 | 31 ± 0.6# | 23 ± 2.7 | 22 ± 1.7 | 33 ± 0.4 | 33 ± 0.1$$ | 26 ± 0.7 | 26 ± 0.9 ¥ |
| 10 | 19 ± 0.5 | 16 ± .2.1 | 20 ± 0.7 | 21 ± 1.4 | 17 ± 0.4 | 18 ± 1.0 | 22 ± 2.0 | 23 ± 1.9 | 18 ± 1.1 | 18 ± 1.4 | |
| 5 | 13 ± 0.7 | 14 ± .0.5 | 10 ± 0.6 | 11 ± 0.6 | 10 ± 0.3 | 9 ± 1.4 | 15 ± 0.7 | 16 ± 2.4 | 11 ± 0.8 | 8 ± 0.4 | |
|
| |||||||||||
|
| 20 | 27 ± 1.0 | 25 ± 0.5 | 33 ± 0.1 | 32 ± 1.9## | 27 ± 1.4 | 28 ± 0.1₫ | 32 ± 0.1 | 32 ± 0.7$$ | 28 ± 0.7 | 29 ± 0.6 ¥ |
| 10 | 19 ± 0.9 | 17 ± .0.1 | 27 ± 1.5 | 27 ± 0.1 | 19 ± 0.4 | 19 ± 1.9 | 27 ± 1.3 | 26 ± 0.5 | 18 ± 2.4 | 17 ± 0.4 | |
| 5 | 12 ± 0.3 | 11 ± .0.8 | 17 ± 0.4 | 13 ± 0.8 | 9 ± 0.3 | 10 ± 0.7 | 13 ± 0.5 | 14 ± 1.3 | 12 ± 0.1 | 11 ± 1.5 | |
|
| |||||||||||
|
| 20 | 32 ± 1.1 | 32 ± 1.2 | 34 ± 0.4 | 31 ± 2.1## | 23 ± 1.3 | 22 ± 0.4 | 29 ± 0.3 | 29 ± 0.4$ | 21 ± 0.3 | 19 ± 0.4 |
| 10 | 26 ± 2.5 | 26 ± 0.3 | 25 ± 0.6 | 24 ± 0.9 | 17 ± 1.7 | 16 ± 0.8 | 20 ± 0.6 | 20 ± 0.4 | 13 ± 0.4 | 14 ± 0.9 | |
| 5 | 13 ± 2.1 | 14 ± .0.8 | 16 ± 0.4 | 17 ± 0.7 | 9 ± 1.7 | 8 ± 0.5 | 15 ± 0.2 | 16 ± 0.7 | 8 ± 1.8 | 8 ± 1.3 | |
|
| |||||||||||
| Combination of three (1 : 1 : 1 ratio) | 20 | 34 ± 0.3 | 33 ± .1.5 | 37 ± 0.2 | 37 ± 1.7## | 22 ± 1.1 | 22 ± 1.6 | 35 ± 1.7 | 35 ± 0.2$$ | 26 ± 0.8 | 26 ± 0.4 ¥ |
| 10 | 26 ± 0.1 | 26 ± .1.1 | 24 ± 0.8 | 25 ± 0.9 | 15 ± 1.2 | 16 ± 0.1 | 25 ± 2.0 | 25 ± 1.4 | 17 ± 0.5 | 17 ± 0.2 | |
| 5 | 17 ± 1.2 | 16 ± .0.9 | 18 ± 0.7 | 18 ± 0.8 | 9 ± 0.7 | 9 ± 0.4 | 16 ± 0.3 | 17 ± 0.9 | 12 ± 0.1 | 11 ± 1.9 | |
|
| |||||||||||
| Positive control | S | R | S | R | S | R | S | R | S | R | |
| Negative control | NI | NI | NI | NI | NI | NI | NI | NI | NI | NI | |
Mean ± SD, whereas C = ciprofloxacin; NI = no inhibition zone; NT = not tested; ATCC = susceptible >21 mm IZ, resistant <16 mm IZ, where P < 0.05 and P < 0.01 when compared to cefoxitin treated MRSA, while #P < 0.05 and ##P < 0.01when compared to modern drug treated E. faecalis;$P < 0.05 and $$P < 0.01 when compared to K. pneumoniae and ¥P < 0.05 when compared to modern drug treated P. aeruginosa, and ₫P < 0.05 when compared to modern drug treated E. coli.
MIC and MBC values of essential oils against human pathogenic bacteria in agar dilution method at KMU, 2020.
| Essential oils extract | Concentratio | Concentration in | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-positive bacteria | Gram-negative bacteria | ||||||||||
|
|
|
|
|
| |||||||
| ATCC | MRSA | ATCC | VRE | ATCC | ESBL | ATCC | MDR | ATCC | ESBL | ||
|
| MIC | 16.0 | 16.0 | 8.0 | 8.0 | 16.0 | 16.0 | 2.0 | 4.0 | 4.0 | 8.0 |
| MBC | 16.0 | 32.0 | 8.0 | 16.0 | 32.0 | 32.0 | 2.0 | 4.0 | 2.0 | 8.0 | |
|
| |||||||||||
|
| MIC | 4.0 | 4.0 | 4.0 | 4.0 | 16.0 | 16.0 | 16.0 | 16.0 | 16.0 | 16.0 |
| MBC | 4.0 | 8.0 | 8.0 | 8.0 | 16.0 | 16.0 | 16.0 | 16.0 | 16.0 | 32.0 | |
|
| |||||||||||
|
| MIC | 8.0 | 8.0 | 16.0 | 16.0 | 32.0 | 32.0 | 4.0 | 4.0 | 16.0 | 16.0 |
| MBC | 8.0 | 16.0 | 16.0 | 16.0 | 16.0 | 16.0 | 4.0 | 8.0 | 32.0 | 32.0 | |
|
| |||||||||||
|
| MIC | 4.0 | 4.0 | 1.0 | 2.0 | 16.0 | 16.0 | 1.0 | 1.0 | 16.0 | 16.0 |
| MBC | 4.0 | 8.0 | 1.0 | 4.0 | 4.0 | 4.0 | 1.0 | 2.0 | 32.0 | 16.0 | |
|
| |||||||||||
|
| MIC | 2.0 | 2.0 | 4.0 | 4.0 | 8.0 | 8.0 | 2.0 | 2.0 | 8.0 | 8.0 |
| MBC | 2.0 | 4.0 | 8.0 | 8.0 | 8.0 | 8.0 | 1.0 | 4.0 | 16.0 | 16.0 | |
|
| |||||||||||
|
| MIC | 1.0 | 1.0 | 1.0 | 1.0 | 4.0 | 4.0 | 1.0 | 1.0 | 2.0 | 8.0 |
| MBC | 2.0 | 2.0 | 1.0 | 1.0 | 2.0 | 4.0 | 1.0 | 1.0 | 4.0 | 4.0 | |
|
| |||||||||||
| Combination of three (1 : 1 : 1 ratio) | MIC | 0.5 | 1.0 | 0.25 | 0.25 | 2.0 | 2.0 | 0.5 | 1.0 | 2.0 | 2.0 |
| MBC | 1.0 | 1.0 | 0.25 | 0.25 | 1.0 | 2.0 | 0.25 | 0.5 | 2.0 | 4.0 | |
|
| |||||||||||
| Modern drug | |||||||||||
ATCC = reference strain for each species; MDR = multidrug-resistant strains; MBC = minimal bactericidal concentration; MIC = minimal inhibitory concentration; NT = not tested; C = 5 μg ciprofloxacin +growth has been seen.
The mean fractional inhibitory concentration index for MDR bacteria at KMU, 2020.
| Mixture of oil in 1 : 1 ratio | Gram positive | Gram negative | |||
|---|---|---|---|---|---|
| MRSA | VRE | MDR | ESBL producing bacteria | ||
|
|
| ||||
|
| 0.75 | 1.25# | 0.625 | 0.75 | 1.0 |
|
| |||||
|
| |||||
|
| 0.75 | 0.375 ¥ | 0.5 | 1.5# | 3.0# |
|
| |||||
|
| |||||
|
| 0.3125 ¥ ¥ | 0.375 ¥ | 0.3125 ¥ | 0.5 | 0.5 |
|
| |||||
The values represent mean fractional inhibitory concentration index (n = 6), where ¥ ¥X = synergy interaction, ¥X = partial synergy, X = indifference interaction, and #X = antagonistic interaction of essential oil.